Media stories about Fluidigm (NASDAQ:FLDM) have trended somewhat positive recently, according to Accern. Accern rates the sentiment of news coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Fluidigm earned a media sentiment score of 0.12 on Accern’s scale. Accern also gave news coverage about the medical research company an impact score of 44.6137766540174 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
These are some of the news articles that may have impacted Accern Sentiment’s scoring:
Separately, ValuEngine upgraded shares of Fluidigm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd.
Fluidigm (NASDAQ FLDM) traded up $0.07 during mid-day trading on Friday, hitting $5.93. 126,349 shares of the stock traded hands, compared to its average volume of 189,292. Fluidigm has a twelve month low of $2.52 and a twelve month high of $8.69. The company has a current ratio of 3.02, a quick ratio of 2.46 and a debt-to-equity ratio of 5.00.
In other news, insider Levin Capital Strategies, L.P. bought 60,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 12th. The shares were purchased at an average price of $5.25 per share, for a total transaction of $315,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have purchased 527,202 shares of company stock worth $2,548,586. 4.70% of the stock is owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/12/09/fluidigm-fldm-receives-coverage-optimism-rating-of-0-12.html.
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Co. and related companies with MarketBeat.com's FREE daily email newsletter.